Compounded NAD+ products deserve a careful discussion about the prescribing decision and the dispensing pharmacy. A professional-looking website, a US address, or a laboratory badge does not independently establish the quality of the medication a person receives.
The FDA has warned about ingredients unsuitable for sterile NAD+ compounding and reported serious reactions associated with injectable products. That notice is a reason to ask specific questions across providers; it is not a finding that every product or brand has the same problem.
Know the prescriber, the pharmacy, and the product. Registration and marketing claims do not replace product-specific questions or FDA approval.
Understand the approval distinction
Compounded drugs are not FDA-approved. That means FDA does not verify their safety, effectiveness, and quality before marketing through the ordinary approval process for finished drugs. A clinician’s license or a facility’s registration is a different matter.
Ask the prescriber why the particular compounded preparation is appropriate for you. Avoid interpreting phrases such as “pharmacy-grade” or “FDA-registered” as proof that the finished NAD+ drug has FDA approval. The FDA compounding Q&A explains the distinction.
What the ingredient warning says
The FDA notice describes concerns about food-grade NAD+ being used to make sterile products and reactions consistent with excessive endotoxins. Reported symptoms included severe chills, shaking, vomiting, and fatigue; some cases required medical treatment.
This is why a generic statement that a product is “pure” is not enough information. Ask the pharmacy about suitability of ingredients for the intended route and the controls used for the preparation. The notice does not tell us which lot a particular reader will receive, so this site cannot use it to certify or condemn that lot.
Our testing-document guide explains why an oral supplement COA does not establish suitability for sterile compounding.
Get the pharmacy’s identity before you need help
Ask for the dispensing pharmacy’s legal name, contact information, and the relevant license details. Check the information with the appropriate state board, using the NABP board directory as a starting point.
If a provider cannot tell you who will dispense until after clinical review, ask when that information will be available and whether you can ask questions before the medication is prepared. Keep the pharmacy contact, label, and lot information together for future questions.
Ask about different quality checks
Product identity, concentration, sterility, and endotoxin control address different concerns. A single favorable result should not be assumed to answer all of them. Ask how the dispensing team evaluates quality and handles an unexpected result or a patient complaint.
The IVY RX review and Eden review discuss their published testing descriptions as provider claims. We have not independently audited those programs or inspected a patient’s lot documentation. A transparent review should preserve that boundary.
Have a plan for a questionable shipment or reaction
If the package is damaged or the storage conditions are uncertain, contact the dispensing pharmacist before using it. Do not assume that normal appearance proves suitability. Keep the packaging and identifying information while the issue is assessed.
Severe symptoms after an injection warrant medical attention; do not dismiss them as proof that the product is working. For trouble breathing, chest pain, fainting, or rapidly worsening symptoms, seek emergency care. Our side-effects guide covers how to prepare a useful report for the clinical team.
Resolve the exact product questions.
FDA status, vial labels and units, and research powders or reconstitution are different questions. Combination products require their own rationale; evidence for one ingredient does not establish benefit from the mixture.
Sources & reading notes
Primary sources checked September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- FDA: ingredients suitable for sterile compounding Safety notice describing reported reactions and ingredient-quality concerns.
- FDA: compounding questions and answers Explains that compounded drugs are not FDA-approved.
- NABP: state boards of pharmacy Directory for checking pharmacy credentials.
- IVY RX: NAD+ Injection Provider lists a starting price of $179/month and describes its testing process.
- Eden: NAD+ Injection Provider advertises $91 for the first month; this is not a verified renewal price.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.